Oral but Not Intravenous Glucose Acutely Decreases Circulating Interleukin-6 Concentrations in Overweight Individuals

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Manning, Patrick J ^a   Sutherland, Wayne H F ^a   Williams, Sheila M ^a   de Jong, Sylvia A ^a   Hendry, Gavin P ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; INTERLEUKIN 6; WATER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; INSULIN BLOOD LEVEL; INTERMETHOD COMPARISON; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; PROTEIN BLOOD LEVEL;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AREA UNDER CURVE; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HEMATOCRIT; HUMANS; INSULIN; INTERLEUKIN-6; MALE; OVERWEIGHT;

EID: 84878930646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066395     Document Type: Article

References (25)

1. Le JM, Vilcek J, (1989) Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61: 588-602.
2. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G, (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-51.
3. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM, (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-34.
4. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, et al. (2008) Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Med 5 (4): e78 doi:]10.1371/journal.pmed.0050078].
5. Manning PJ, Sutherland WHF, Walker RJ, de Jong SA, Berry EA, (2008) The effect of glucose ingestion on inflammation and oxidative stress in obese individuals. Metabolism 57: 1345-9.
6. Manning PJ, Sutherland WHF, McGrath MM, de Jong SA, Walker RJ, et al. (2008) Postprandial Cytokine Concentrations and Meal Composition in Obese and Lean Women. Obesity 16: 2046-2052.
7. Lundman P, Boquist S, Samnegård A, Bennermo M, Held C, et al. (2007) A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr Metab Cardiovasc Diseases 17: 195-202.
8. Manning PJ, Sutherland WH, Hendry G, de Jong SA, McGrath MM, et al. (2004) Changes in circulating postprandial proinflammatory cytokine concentrations in diet-controlled type 2 diabetes and the effect of ingested fat. Diabetes Care 27: 2509-11.
9. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al. (2001) Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86: 3257-65.
10. Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, et al. (2006) Glucose ingestion induces an increase in intranuclear factor κB, a fall in cellular inhibitor messenger RNA by mononuclear cells in healthy human subjects. Metabolism 55: 1177-1185.
11. Dandona P, Chaudhuri A, Ghanim H, Mohanty P, (2007) Proinflammatory effects of glucose and anti-inflammatory effect of insulin: Relevance to cardiovascular disease. Am J Cardiol 99 (suppl): 15B-26B.
12. Beisswenger PJ, Brown VW, Ceriello A, Le A, Goldberg RB, et al. (2011) Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes. Diabetic Med 28: 1088-1095.
13. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, et al. (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation 106: 2067-2072.
14. Mathews JNS, Altman DG, Campbell MJ, Royston P, (1990) Analysis of serial measurements in medical research. BMJ 300: 230-235.
15. Dandona P, Aljada A, Mohanty P, (2002) The anti-inflammatory and potentially anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45: 924-930.
16. Ghanim H, Korzeniewski K, Sia CL, Abuaysheh S, Lohano T, et al. (2010) Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care 33: 1103-1108.
17. Holmer-Jensen H, Karhu T, Mortensen LS, Pedersen SB, Herzig KH, et al. (2011) Differential effects of dietary protein sources on postprandial low-grade inflammation after a single high fat meal in obese non-diabetic subjects. Nutrition Journal 10: 115.
18. Charo IF, Ranshoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
19. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505.
20. Yu R, Kim CS, Kwon BS, Kawada T, (2006) Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity 14: 1353-1362.
21. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, et al. (2012) Exenatide exerts a potent anti-inflammatory effect. J Clin Endocrinol Metab 97(1): 198-207.
22. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, et al. (2012) Sitagliptin exerts an anti-inflammatory action. J Clin Endocrinol Metab 97 (9): 3333-41.
23. Shoelsen SE, Lee J, Goldfine AB, (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
24. Donath MY, Halban PA, (2004) Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47 (3): 581-589.
25. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patients. J Clin Endocrinol Metab 86 (8): 3717-23.